ASH 2024 | Acimtamig with off-the-shelf allogeneic NK-cells in R/R cHL

So that is a really exciting study. It is evaluating AFM13, which is a bispecific antibody targeting CD30 and CD16A. So it’s meant to redirect NK-cells to the tumor cells. It’s being given along with cord-derived NK-cells. And this combination has previously been found to be very active in a smaller study, and this is a larger study to confirm the efficacy, particularly right now in Hodgkin lymphoma. And so the data that was reported at ASH included 22 patients, and the activity does appear to be quite high in Hodgkin lymphoma. And particularly, this is a patient population who received all of the most common or all of the most active drugs already, they’ve already been exposed to brentuximab and checkpoint inhibitors. And so these are the patients who really don’t have significant, like, you know, a great number of treatment options. And so the activity so far is looking great. The part of the study that was reported is really still a dose escalation part. And so the next step will be evaluating that data and figuring out the optimal dose to go forward. And I’m really excited about that study because not only will it be expanding in Hodgkin lymphoma, but also be expanding in CD30 positive T-cell lymphomas. And that’s an area where we really have limited treatment options and is really an area of unmet need.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.